Genetics in clinical trials

James F. Meschia, Katrina Gwinn

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pharmacogenetics is founded on longstanding traditions in clinical practice, where therapies are selected based on history and physical findings in order to maximize benefit and minimize risk. Genetic tools allow increased sophistication in patient profiling and treatment optimization. Pharmaceutical companies are aware of the value of collecting genetic data during their clinical trials [17, 18]. Pharmacogenetics research is bidirectional with clinical trials: efficacy data are correlated with genetic polymorphisms, which in turn define subjects for treatment stratification. Currently, pharmacogenetics is in its infancy. Nonetheless, we anticipate that the identification of disease-specific genes will result in earlier diagnostic measures, disease progression markers and targets for therapeutic discovery.

Original languageEnglish (US)
Title of host publicationClinical Trials in the Neurosciences
Pages152-157
Number of pages6
DOIs
StatePublished - Aug 14 2009

Publication series

NameFrontiers of Neurology and Neuroscience
Volume25
ISSN (Print)1660-4431
ISSN (Electronic)1662-2804

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Genetics in clinical trials'. Together they form a unique fingerprint.

  • Cite this

    Meschia, J. F., & Gwinn, K. (2009). Genetics in clinical trials. In Clinical Trials in the Neurosciences (pp. 152-157). (Frontiers of Neurology and Neuroscience; Vol. 25). https://doi.org/10.1159/000209494